Want to see AUPH full AI Analyst Report?
AUPH Stock Chart & Stats
$16.75
<$0.01(0.07%)
At close: 4:00 PM EDT
$16.75
<$0.01(0.07%)
Day’s Range― - ―
52-Week Range$10.34 - $19.25
Previous CloseN/A
Volume414.45K
Average Volume (3M)1.12M
Market Cap
$2.14B
Enterprise Value$1.89K
Total Cash (Recent Filing)$443.12M
Total Debt (Recent Filing)$60.42M
Price to Earnings (P/E)6.9
Beta0.22
Next Earnings
Oct 29, 2026EPS Estimate
0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.36
Shares Outstanding133,051,160
10 Day Avg. Volume1,086,858
30 Day Avg. Volume1,117,659
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)3.69
Price to Sales (P/S)7.57
P/FCF Ratio15.83
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$18.00Price Target Upside7.46% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)0.95
Revenue Forecast (FY)$331.35M
Bulls Say, Bears Say
Bulls Say
Growing LUPKYNIS Commercial SalesReiterated revenue and product-sales growth indicates continued LUPKYNIS adoption and provides a durable commercial base. Sustained growth should improve operating leverage and strengthen Aurinia’s ability to fund its pipeline.
Extended U.S. Patent ExclusivityThe settlement protects U.S. voclosporin exclusivity for roughly another decade, supporting revenue durability and reducing near-term generic erosion risk. It also validates key patents while Aurinia continues defending the franchise.
Improved Cash Generation And Balance SheetPositive and growing free cash flow, alongside modest leverage and a large equity base, improves financial resilience. This gives Aurinia more capacity to support commercialization, pursue development programs, and withstand operating variability.
Bears Say
Uncertain Sustainability Of Recent ProfitabilityThe recent earnings improvement has a short track record, and unusually high margins may not fully represent recurring product economics. Episodic license or royalty income could make future profitability less predictable than reported results suggest.
Dependence On A Single Commercial ProductReliance on LUPKYNIS concentrates revenue in one therapy, leaving the business exposed to clinical, reimbursement, pricing, manufacturing, and adoption risks. Pipeline expansion may help diversify earnings, but those programs are not yet established commercial contributors.
Ongoing Generic Litigation RiskAlthough the Teva settlement extends expected exclusivity, multiple generic challenges remain active. Adverse rulings, settlements, or earlier-entry contingencies could weaken long-term protection for voclosporin and pressure the company’s primary revenue stream.
Aurinia Pharmaceuticals News
AUPH FAQ
What was Aurinia Pharmaceuticals’s price range in the past 12 months?
Aurinia Pharmaceuticals lowest stock price was $10.34 and its highest was $19.25 in the past 12 months.
What is Aurinia Pharmaceuticals’s market cap?
Aurinia Pharmaceuticals’s market cap is $2.14B.
When is Aurinia Pharmaceuticals’s upcoming earnings report date?
Aurinia Pharmaceuticals’s upcoming earnings report date is Oct 29, 2026 which is in 55 days.
How were Aurinia Pharmaceuticals’s earnings last quarter?
Aurinia Pharmaceuticals released its earnings results on Aug 06, 2026. The company reported $0.28 earnings per share for the quarter, beating the consensus estimate of $0.24 by $0.04.
Is Aurinia Pharmaceuticals overvalued?
According to Wall Street analysts Aurinia Pharmaceuticals’s price is currently Undervalued.
Does Aurinia Pharmaceuticals pay dividends?
Aurinia Pharmaceuticals does not currently pay dividends.
What is Aurinia Pharmaceuticals’s EPS estimate?
Aurinia Pharmaceuticals’s EPS estimate is 0.22.
How many shares outstanding does Aurinia Pharmaceuticals have?
Aurinia Pharmaceuticals has 133,051,160 shares outstanding.
What happened to Aurinia Pharmaceuticals’s price movement after its last earnings report?
Aurinia Pharmaceuticals reported an EPS of $0.28 in its last earnings report, beating expectations of $0.24. Following the earnings report the stock price went up 6.188%.
Which hedge fund is a major shareholder of Aurinia Pharmaceuticals?
Currently, no hedge funds are holding shares in AUPH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aurinia Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$18.00 (7.46% Upside)
$18.00 (7.46% Upside)
Blogger Sentiment
Bullish
AUPH Sentiment 90%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.2%
Last 30 Days ▼ 6.9%
Last 30 Days ▼ 6.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
39.46%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
57.64%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical company, specializing in the development and commercialization of innovative therapies. Its core mission is to address a variety of diseases for which current medical solutions are inadequate, serving patient populations across the United States and internationally. The company's flagship product is LUPKYNIS, an approved treatment designed for adult individuals suffering from active lupus nephritis. Furthermore, Aurinia maintains a strategic collaboration and licensing agreement with Otsuka Pharmaceutical Co., Ltd. The firm's main corporate office is located in Victoria, Canada.
AUPH Revenue Breakdown
90.00% U.S.
10.00% Japan
AUPH Stock 12 Month Forecast
Average Price Target
$18.00
▲(7.46% Upside)
Technical Analysis
Ownership Overview
12.80% Insiders
4.56% Mutual Funds
19.50% Other Institutional Investors
55.94% Public Companies and
Individual Investors